logo-loader

AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

Last updated: 11:13 21 Jan 2013 GMT, First published: 12:13 21 Jan 2013 GMT

no_picture_pai

SoGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca (LON:AZN).

Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta.

It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently projecting.

However, it sees challenges for Brilinta: “Our forecasts for sales are significantly below consensus because we see multiple hurdles to its use in the US, such as the negative US data from the PLATO study, which deters doctors from prescribing it, an unhelpful twice daily dosing regimen, and an interaction with statins (which is absent in competitors clopidogrel and Effient).”

At midday the shares were changing hands for £30.67, down 9.5p on the day.

 

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 6 minutes ago